AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 103 filers reported holding AKERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 4.79 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $8,766,000 | -32.9% | 617,727 | 0.0% | 8.75% | +25.2% |
| Q4 2021 | $13,065,000 | -5.4% | 617,727 | 0.0% | 6.99% | +22.3% |
| Q3 2021 | $13,806,000 | -9.9% | 617,727 | 0.0% | 5.72% | +12.6% |
| Q2 2021 | $15,326,000 | -14.5% | 617,727 | 0.0% | 5.08% | +45.5% |
| Q1 2021 | $17,920,000 | -10.7% | 617,727 | -20.6% | 3.49% | +67.5% |
| Q4 2020 | $20,065,000 | -16.2% | 777,727 | 0.0% | 2.08% | -52.5% |
| Q3 2020 | $23,946,000 | -100.0% | 777,727 | -63.2% | 4.38% | -42.1% |
| Q2 2020 | $52,717,114,000 | -9.1% | 2,115,454 | -22.7% | 7.57% | -52.4% |
| Q1 2020 | $58,015,326,000 | – | 2,736,572 | – | 15.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |